Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tablets | 105 | 2025 | 125 | 28.350 |
Why?
|
Drug Compounding | 66 | 2025 | 85 | 18.360 |
Why?
|
Powders | 76 | 2025 | 80 | 17.080 |
Why?
|
Excipients | 51 | 2025 | 54 | 16.390 |
Why?
|
Chemistry, Pharmaceutical | 48 | 2025 | 66 | 11.530 |
Why?
|
Cellulose | 35 | 2025 | 58 | 8.960 |
Why?
|
Solubility | 47 | 2025 | 185 | 8.430 |
Why?
|
Crystallization | 52 | 2025 | 216 | 8.260 |
Why?
|
Tensile Strength | 43 | 2025 | 82 | 7.760 |
Why?
|
Technology, Pharmaceutical | 25 | 2024 | 33 | 6.780 |
Why?
|
Particle Size | 42 | 2025 | 126 | 5.820 |
Why?
|
Stearic Acids | 10 | 2023 | 11 | 3.920 |
Why?
|
Pharmaceutical Preparations | 12 | 2022 | 92 | 3.880 |
Why?
|
Pressure | 21 | 2025 | 167 | 3.810 |
Why?
|
Lactose | 13 | 2019 | 27 | 3.530 |
Why?
|
Surface-Active Agents | 6 | 2024 | 61 | 3.190 |
Why?
|
Water | 17 | 2025 | 286 | 3.120 |
Why?
|
Berberine | 4 | 2023 | 8 | 3.030 |
Why?
|
Hardness | 17 | 2024 | 21 | 2.980 |
Why?
|
Carbamazepine | 5 | 2024 | 10 | 2.700 |
Why?
|
Thiazines | 6 | 2025 | 6 | 2.670 |
Why?
|
Drug Stability | 18 | 2025 | 52 | 2.600 |
Why?
|
Porosity | 26 | 2024 | 61 | 2.540 |
Why?
|
Silicon Dioxide | 8 | 2022 | 40 | 2.370 |
Why?
|
Sodium Dodecyl Sulfate | 5 | 2021 | 25 | 2.330 |
Why?
|
Biological Availability | 6 | 2024 | 91 | 2.270 |
Why?
|
Drug Liberation | 12 | 2024 | 16 | 2.200 |
Why?
|
Lubricants | 4 | 2020 | 7 | 2.090 |
Why?
|
Taste | 3 | 2020 | 28 | 1.970 |
Why?
|
Salts | 3 | 2025 | 17 | 1.860 |
Why?
|
Pyrazines | 3 | 2024 | 91 | 1.720 |
Why?
|
Duodenum | 2 | 2024 | 105 | 1.670 |
Why?
|
Ibuprofen | 6 | 2023 | 29 | 1.640 |
Why?
|
X-Ray Diffraction | 16 | 2025 | 128 | 1.630 |
Why?
|
Povidone | 6 | 2024 | 8 | 1.610 |
Why?
|
Surface Properties | 15 | 2020 | 131 | 1.610 |
Why?
|
Celecoxib | 7 | 2023 | 31 | 1.600 |
Why?
|
Pyrrolidines | 4 | 2024 | 60 | 1.560 |
Why?
|
Drug Industry | 3 | 2022 | 54 | 1.550 |
Why?
|
Mannitol | 4 | 2019 | 50 | 1.550 |
Why?
|
Flucytosine | 3 | 2016 | 11 | 1.430 |
Why?
|
Drug Delivery Systems | 5 | 2022 | 178 | 1.430 |
Why?
|
Administration, Oral | 11 | 2024 | 667 | 1.340 |
Why?
|
Polymers | 7 | 2024 | 196 | 1.340 |
Why?
|
Piroxicam | 2 | 2020 | 11 | 1.340 |
Why?
|
Coumaric Acids | 2 | 2019 | 6 | 1.320 |
Why?
|
Glutarates | 2 | 2020 | 8 | 1.320 |
Why?
|
Ritonavir | 2 | 2019 | 12 | 1.310 |
Why?
|
Antifungal Agents | 5 | 2024 | 123 | 1.310 |
Why?
|
Drug Carriers | 3 | 2020 | 82 | 1.300 |
Why?
|
Models, Chemical | 8 | 2018 | 179 | 1.240 |
Why?
|
Diphenhydramine | 2 | 2018 | 17 | 1.210 |
Why?
|
Acetaminophen | 4 | 2020 | 57 | 1.210 |
Why?
|
Solvents | 5 | 2025 | 97 | 1.180 |
Why?
|
Theophylline | 5 | 2024 | 34 | 1.170 |
Why?
|
X-Ray Microtomography | 2 | 2024 | 91 | 1.140 |
Why?
|
Triazoles | 2 | 2024 | 104 | 1.130 |
Why?
|
Oxalic Acid | 2 | 2019 | 8 | 1.110 |
Why?
|
Glucuronosyltransferase | 4 | 2014 | 186 | 1.090 |
Why?
|
Nanoparticles | 6 | 2019 | 165 | 1.090 |
Why?
|
Calcium Phosphates | 3 | 2017 | 78 | 1.090 |
Why?
|
Citric Acid | 3 | 2018 | 44 | 1.080 |
Why?
|
Physical Phenomena | 2 | 2023 | 7 | 1.080 |
Why?
|
4-Aminobenzoic Acid | 3 | 2024 | 6 | 1.070 |
Why?
|
Helium | 2 | 2023 | 10 | 1.030 |
Why?
|
Levofloxacin | 1 | 2025 | 8 | 0.980 |
Why?
|
Wettability | 8 | 2024 | 8 | 0.980 |
Why?
|
Trimetazidine | 1 | 2025 | 4 | 0.980 |
Why?
|
Calorimetry, Differential Scanning | 8 | 2024 | 13 | 0.960 |
Why?
|
Oxalates | 1 | 2025 | 49 | 0.960 |
Why?
|
Analgesics, Non-Narcotic | 2 | 2016 | 49 | 0.900 |
Why?
|
Humidity | 9 | 2023 | 91 | 0.890 |
Why?
|
Stress, Mechanical | 4 | 2019 | 253 | 0.890 |
Why?
|
Emulsions | 2 | 2020 | 19 | 0.870 |
Why?
|
Aspirin | 2 | 2022 | 162 | 0.830 |
Why?
|
Elastic Modulus | 4 | 2025 | 37 | 0.820 |
Why?
|
Kinetics | 9 | 2024 | 1534 | 0.810 |
Why?
|
Emollients | 1 | 2022 | 3 | 0.810 |
Why?
|
Gastric Juice | 1 | 2022 | 15 | 0.810 |
Why?
|
Compressive Strength | 8 | 2017 | 24 | 0.770 |
Why?
|
Models, Theoretical | 5 | 2025 | 493 | 0.760 |
Why?
|
Dicarboxylic Acids | 1 | 2021 | 23 | 0.740 |
Why?
|
Vinyl Compounds | 3 | 2024 | 7 | 0.740 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2025 | 244 | 0.720 |
Why?
|
Allelic Imbalance | 2 | 2011 | 22 | 0.720 |
Why?
|
Histamine H1 Antagonists, Non-Sedating | 1 | 2020 | 15 | 0.710 |
Why?
|
Loratadine | 1 | 2020 | 21 | 0.710 |
Why?
|
Parabens | 3 | 2019 | 4 | 0.700 |
Why?
|
Diffusion | 4 | 2021 | 93 | 0.700 |
Why?
|
Norfloxacin | 1 | 2019 | 5 | 0.690 |
Why?
|
Sweetening Agents | 1 | 2020 | 17 | 0.690 |
Why?
|
Poloxamer | 1 | 2019 | 29 | 0.680 |
Why?
|
Temperature | 9 | 2024 | 409 | 0.670 |
Why?
|
Microscopy, Electron, Scanning | 7 | 2021 | 141 | 0.650 |
Why?
|
Research Design | 1 | 2022 | 591 | 0.640 |
Why?
|
Ionic Liquids | 1 | 2018 | 1 | 0.630 |
Why?
|
Naproxen | 1 | 2018 | 14 | 0.620 |
Why?
|
Quality Control | 4 | 2024 | 117 | 0.610 |
Why?
|
Fumarates | 1 | 2018 | 19 | 0.600 |
Why?
|
Rheology | 6 | 2024 | 41 | 0.600 |
Why?
|
Niacinamide | 3 | 2021 | 98 | 0.600 |
Why?
|
Chemical Engineering | 1 | 2017 | 2 | 0.590 |
Why?
|
Histamine H1 Antagonists | 1 | 2017 | 40 | 0.580 |
Why?
|
Hardness Tests | 2 | 2015 | 3 | 0.580 |
Why?
|
Powder Diffraction | 4 | 2023 | 4 | 0.540 |
Why?
|
Hydrochloric Acid | 2 | 2016 | 11 | 0.540 |
Why?
|
Succinic Acid | 1 | 2015 | 7 | 0.520 |
Why?
|
Algorithms | 3 | 2017 | 1913 | 0.510 |
Why?
|
Metformin | 1 | 2017 | 124 | 0.510 |
Why?
|
Thermodynamics | 5 | 2024 | 314 | 0.510 |
Why?
|
Felodipine | 1 | 2014 | 1 | 0.480 |
Why?
|
Hydrogen-Ion Concentration | 3 | 2022 | 503 | 0.480 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2014 | 2415 | 0.470 |
Why?
|
Dipyridamole | 2 | 2024 | 14 | 0.460 |
Why?
|
Chemical Precipitation | 4 | 2020 | 18 | 0.450 |
Why?
|
Hydrogen Bonding | 3 | 2025 | 145 | 0.440 |
Why?
|
Phase Transition | 4 | 2020 | 18 | 0.440 |
Why?
|
Linkage Disequilibrium | 2 | 2011 | 477 | 0.420 |
Why?
|
Molecular Structure | 5 | 2020 | 293 | 0.410 |
Why?
|
Stomach | 2 | 2024 | 111 | 0.410 |
Why?
|
Flurbiprofen | 1 | 2012 | 1 | 0.400 |
Why?
|
Glass | 1 | 2011 | 15 | 0.390 |
Why?
|
Vitamin B Complex | 1 | 2012 | 21 | 0.390 |
Why?
|
Models, Molecular | 6 | 2022 | 1315 | 0.390 |
Why?
|
Transition Temperature | 5 | 2024 | 11 | 0.380 |
Why?
|
Magnetic Resonance Spectroscopy | 3 | 2024 | 316 | 0.380 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2010 | 313 | 0.380 |
Why?
|
Regulatory Elements, Transcriptional | 1 | 2011 | 46 | 0.370 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 3 | 2019 | 95 | 0.370 |
Why?
|
Enhancer Elements, Genetic | 2 | 2011 | 284 | 0.370 |
Why?
|
3' Untranslated Regions | 1 | 2011 | 95 | 0.370 |
Why?
|
Analgesics | 1 | 2012 | 119 | 0.370 |
Why?
|
Crystallography, X-Ray | 3 | 2025 | 491 | 0.360 |
Why?
|
Spectroscopy, Near-Infrared | 2 | 2024 | 36 | 0.360 |
Why?
|
Climate | 1 | 2010 | 58 | 0.350 |
Why?
|
Materials Testing | 2 | 2019 | 93 | 0.350 |
Why?
|
Hypromellose Derivatives | 2 | 2020 | 4 | 0.350 |
Why?
|
Adhesiveness | 2 | 2020 | 4 | 0.330 |
Why?
|
Rats, Sprague-Dawley | 2 | 2024 | 1237 | 0.330 |
Why?
|
Sildenafil Citrate | 2 | 2020 | 23 | 0.310 |
Why?
|
Liver | 2 | 2011 | 1211 | 0.300 |
Why?
|
Adaptation, Physiological | 1 | 2010 | 318 | 0.300 |
Why?
|
Methylcellulose | 2 | 2019 | 6 | 0.290 |
Why?
|
Biocompatible Materials | 1 | 2009 | 198 | 0.290 |
Why?
|
Alternative Splicing | 1 | 2009 | 212 | 0.290 |
Why?
|
Biological Products | 2 | 2021 | 161 | 0.290 |
Why?
|
Reproducibility of Results | 5 | 2020 | 2770 | 0.290 |
Why?
|
Organic Chemicals | 1 | 2007 | 34 | 0.280 |
Why?
|
Gene Expression Regulation | 3 | 2010 | 1983 | 0.270 |
Why?
|
Aspartame | 1 | 2006 | 5 | 0.270 |
Why?
|
Desiccation | 2 | 2019 | 6 | 0.260 |
Why?
|
Elasticity | 2 | 2017 | 97 | 0.260 |
Why?
|
Rats | 2 | 2024 | 4048 | 0.250 |
Why?
|
Breast Neoplasms | 3 | 2020 | 3022 | 0.250 |
Why?
|
Diclofenac | 1 | 2025 | 4 | 0.250 |
Why?
|
Picolinic Acids | 1 | 2025 | 6 | 0.250 |
Why?
|
Pyrazoles | 1 | 2006 | 150 | 0.240 |
Why?
|
Curcumin | 2 | 2015 | 18 | 0.240 |
Why?
|
Drugs, Chinese Herbal | 2 | 2015 | 67 | 0.240 |
Why?
|
Pharmacopoeias as Topic | 1 | 2024 | 1 | 0.240 |
Why?
|
Databases, Factual | 2 | 2014 | 866 | 0.240 |
Why?
|
Nifedipine | 1 | 2024 | 26 | 0.230 |
Why?
|
Crystallography | 3 | 2021 | 45 | 0.230 |
Why?
|
Animals | 7 | 2024 | 27536 | 0.230 |
Why?
|
Acetazolamide | 1 | 2024 | 11 | 0.230 |
Why?
|
Lubrication | 1 | 2023 | 2 | 0.230 |
Why?
|
Humans | 22 | 2024 | 90014 | 0.230 |
Why?
|
Gastric Mucosa | 1 | 2024 | 68 | 0.220 |
Why?
|
Permeability | 2 | 2023 | 138 | 0.220 |
Why?
|
Sulfonamides | 1 | 2006 | 320 | 0.220 |
Why?
|
Proteins | 1 | 2009 | 787 | 0.220 |
Why?
|
Molecular Dynamics Simulation | 2 | 2023 | 265 | 0.210 |
Why?
|
Pharmaceutical Research | 1 | 2022 | 2 | 0.210 |
Why?
|
Genotype | 4 | 2014 | 1852 | 0.210 |
Why?
|
Genetic Variation | 1 | 2010 | 1380 | 0.210 |
Why?
|
Chlorides | 1 | 2023 | 104 | 0.210 |
Why?
|
Commerce | 1 | 2022 | 31 | 0.210 |
Why?
|
Carboxylic Acids | 1 | 2022 | 17 | 0.200 |
Why?
|
Erlotinib Hydrochloride | 1 | 2022 | 88 | 0.200 |
Why?
|
Dry Powder Inhalers | 1 | 2021 | 3 | 0.190 |
Why?
|
Chitosan | 2 | 2019 | 17 | 0.190 |
Why?
|
Mentors | 1 | 2022 | 90 | 0.190 |
Why?
|
Equipment Design | 3 | 2019 | 422 | 0.190 |
Why?
|
Micelles | 2 | 2018 | 48 | 0.190 |
Why?
|
Structure-Activity Relationship | 3 | 2019 | 417 | 0.180 |
Why?
|
Gene Frequency | 3 | 2014 | 687 | 0.180 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2021 | 65 | 0.180 |
Why?
|
Spectroscopy, Fourier Transform Infrared | 3 | 2021 | 30 | 0.180 |
Why?
|
Dogs | 1 | 2021 | 706 | 0.180 |
Why?
|
Flavoring Agents | 1 | 2020 | 11 | 0.180 |
Why?
|
Binding Sites | 3 | 2019 | 1122 | 0.180 |
Why?
|
Principal Component Analysis | 2 | 2018 | 161 | 0.180 |
Why?
|
Regulatory-Associated Protein of mTOR | 2 | 2010 | 11 | 0.170 |
Why?
|
Saccharin | 1 | 2020 | 9 | 0.170 |
Why?
|
Nitrobenzoates | 1 | 2019 | 2 | 0.170 |
Why?
|
Albendazole | 1 | 2019 | 3 | 0.170 |
Why?
|
Chromatin Immunoprecipitation | 2 | 2010 | 137 | 0.170 |
Why?
|
Least-Squares Analysis | 2 | 2017 | 48 | 0.170 |
Why?
|
Talc | 1 | 2019 | 4 | 0.170 |
Why?
|
Photoelectron Spectroscopy | 1 | 2019 | 2 | 0.170 |
Why?
|
Sodium Chloride | 1 | 2019 | 88 | 0.160 |
Why?
|
Muramidase | 1 | 2019 | 35 | 0.160 |
Why?
|
Indomethacin | 1 | 2019 | 59 | 0.160 |
Why?
|
Serum Albumin, Bovine | 1 | 2019 | 45 | 0.160 |
Why?
|
Drug Storage | 1 | 2018 | 4 | 0.160 |
Why?
|
Caffeine | 1 | 2019 | 83 | 0.160 |
Why?
|
Printing, Three-Dimensional | 1 | 2019 | 45 | 0.160 |
Why?
|
Breast | 2 | 2011 | 292 | 0.150 |
Why?
|
Viscosity | 1 | 2017 | 46 | 0.150 |
Why?
|
Prevalence | 1 | 2021 | 1250 | 0.140 |
Why?
|
Glucosides | 1 | 2017 | 13 | 0.140 |
Why?
|
Benzhydryl Compounds | 1 | 2017 | 44 | 0.140 |
Why?
|
Adsorption | 1 | 2016 | 53 | 0.140 |
Why?
|
Stilbenes | 1 | 2016 | 25 | 0.130 |
Why?
|
Polyethylene Glycols | 2 | 2015 | 360 | 0.130 |
Why?
|
Specific Gravity | 2 | 2005 | 4 | 0.130 |
Why?
|
Sulfamerazine | 2 | 2005 | 2 | 0.130 |
Why?
|
Polyvinyls | 1 | 2015 | 17 | 0.130 |
Why?
|
Salvia miltiorrhiza | 1 | 2015 | 3 | 0.130 |
Why?
|
Amlodipine | 1 | 2015 | 5 | 0.130 |
Why?
|
Double-Blind Method | 1 | 2020 | 1714 | 0.130 |
Why?
|
Time Factors | 4 | 2019 | 5361 | 0.130 |
Why?
|
Glyburide | 1 | 2015 | 32 | 0.130 |
Why?
|
Pharmaceutic Aids | 1 | 2015 | 2 | 0.130 |
Why?
|
Cell Line | 2 | 2011 | 2495 | 0.120 |
Why?
|
Friction | 1 | 2015 | 4 | 0.120 |
Why?
|
Nanocapsules | 1 | 2015 | 11 | 0.120 |
Why?
|
Heating | 1 | 2014 | 14 | 0.120 |
Why?
|
Nanotechnology | 1 | 2015 | 68 | 0.120 |
Why?
|
Monte Carlo Method | 1 | 2015 | 186 | 0.120 |
Why?
|
Rabbits | 1 | 2015 | 640 | 0.120 |
Why?
|
Hypoglycemic Agents | 1 | 2017 | 352 | 0.120 |
Why?
|
Male | 4 | 2024 | 42705 | 0.110 |
Why?
|
Thermogravimetry | 1 | 2013 | 1 | 0.110 |
Why?
|
Bayes Theorem | 1 | 2015 | 382 | 0.110 |
Why?
|
Carboxylic Ester Hydrolases | 1 | 2012 | 24 | 0.100 |
Why?
|
Female | 6 | 2020 | 46617 | 0.100 |
Why?
|
Molecular Conformation | 1 | 2012 | 96 | 0.100 |
Why?
|
Protein Engineering | 1 | 2012 | 145 | 0.100 |
Why?
|
Models, Statistical | 1 | 2015 | 576 | 0.090 |
Why?
|
Regression Analysis | 1 | 2013 | 591 | 0.090 |
Why?
|
HapMap Project | 1 | 2011 | 47 | 0.090 |
Why?
|
Manufactured Materials | 1 | 2010 | 2 | 0.090 |
Why?
|
Dosage Forms | 1 | 2010 | 7 | 0.090 |
Why?
|
Alleles | 2 | 2014 | 1137 | 0.090 |
Why?
|
Octamer Transcription Factor-1 | 1 | 2010 | 19 | 0.090 |
Why?
|
Retinoids | 1 | 2010 | 18 | 0.090 |
Why?
|
Retinoid X Receptors | 1 | 2010 | 39 | 0.090 |
Why?
|
Tetrahydronaphthalenes | 1 | 2010 | 16 | 0.090 |
Why?
|
Transcription Initiation Site | 1 | 2010 | 46 | 0.090 |
Why?
|
Benzoates | 1 | 2010 | 33 | 0.090 |
Why?
|
Hep G2 Cells | 1 | 2010 | 48 | 0.090 |
Why?
|
Computer Simulation | 1 | 2015 | 1102 | 0.090 |
Why?
|
Mammography | 1 | 2014 | 475 | 0.090 |
Why?
|
Geography | 1 | 2010 | 227 | 0.080 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2010 | 43 | 0.080 |
Why?
|
Malonates | 1 | 2009 | 11 | 0.080 |
Why?
|
Urea | 1 | 2009 | 59 | 0.080 |
Why?
|
Dinucleotide Repeats | 1 | 2009 | 14 | 0.080 |
Why?
|
Odds Ratio | 1 | 2011 | 682 | 0.080 |
Why?
|
Haplotypes | 1 | 2011 | 637 | 0.080 |
Why?
|
Organ Specificity | 1 | 2010 | 277 | 0.080 |
Why?
|
Down-Regulation | 1 | 2010 | 521 | 0.080 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 269 | 0.080 |
Why?
|
Drug Design | 1 | 2009 | 126 | 0.080 |
Why?
|
Introns | 1 | 2009 | 301 | 0.070 |
Why?
|
Research | 1 | 2009 | 251 | 0.070 |
Why?
|
Sequence Analysis, DNA | 1 | 2011 | 869 | 0.070 |
Why?
|
Young Adult | 1 | 2020 | 6418 | 0.070 |
Why?
|
Genetics, Population | 1 | 2010 | 407 | 0.070 |
Why?
|
Scattering, Radiation | 2 | 2019 | 117 | 0.070 |
Why?
|
Selection, Genetic | 1 | 2011 | 515 | 0.070 |
Why?
|
Protein Binding | 1 | 2010 | 1492 | 0.070 |
Why?
|
Gene Expression | 1 | 2011 | 1309 | 0.070 |
Why?
|
Case-Control Studies | 1 | 2011 | 1868 | 0.070 |
Why?
|
Stereoisomerism | 1 | 2006 | 102 | 0.070 |
Why?
|
Light | 2 | 2019 | 292 | 0.070 |
Why?
|
Spectrum Analysis, Raman | 2 | 2021 | 15 | 0.060 |
Why?
|
Mathematics | 1 | 2005 | 191 | 0.060 |
Why?
|
Base Sequence | 1 | 2009 | 2329 | 0.060 |
Why?
|
Amides | 1 | 2025 | 54 | 0.060 |
Why?
|
Therapeutic Equivalency | 1 | 2024 | 16 | 0.060 |
Why?
|
Anti-Infective Agents | 1 | 2005 | 91 | 0.060 |
Why?
|
Cell Line, Tumor | 1 | 2010 | 2588 | 0.060 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 3024 | 0.060 |
Why?
|
Chemistry, Physical | 1 | 2004 | 29 | 0.060 |
Why?
|
Chemical Phenomena | 1 | 2004 | 72 | 0.060 |
Why?
|
Genome, Human | 1 | 2009 | 791 | 0.060 |
Why?
|
Caco-2 Cells | 1 | 2023 | 123 | 0.060 |
Why?
|
Intestinal Absorption | 1 | 2023 | 125 | 0.050 |
Why?
|
Healthy Volunteers | 1 | 2024 | 146 | 0.050 |
Why?
|
Academies and Institutes | 1 | 2023 | 33 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2009 | 1452 | 0.050 |
Why?
|
RNA, Messenger | 1 | 2009 | 2026 | 0.050 |
Why?
|
Linear Models | 1 | 2004 | 422 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2007 | 1732 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 1 | 2011 | 2360 | 0.050 |
Why?
|
Aerosols | 1 | 2021 | 47 | 0.050 |
Why?
|
Chromatography, Gel | 1 | 2021 | 103 | 0.050 |
Why?
|
Circular Dichroism | 1 | 2021 | 117 | 0.050 |
Why?
|
History, 20th Century | 1 | 2022 | 315 | 0.050 |
Why?
|
Phospholipids | 1 | 2021 | 112 | 0.050 |
Why?
|
Administration, Inhalation | 1 | 2021 | 192 | 0.050 |
Why?
|
Valproic Acid | 1 | 2021 | 24 | 0.050 |
Why?
|
Pyrans | 1 | 2020 | 10 | 0.050 |
Why?
|
Phenotype | 2 | 2020 | 2457 | 0.050 |
Why?
|
Freezing | 1 | 2020 | 33 | 0.050 |
Why?
|
Microscopy, Electron, Transmission | 2 | 2015 | 136 | 0.050 |
Why?
|
Risk Factors | 1 | 2011 | 5562 | 0.040 |
Why?
|
Adult | 1 | 2020 | 26836 | 0.040 |
Why?
|
Materials Science | 1 | 2019 | 1 | 0.040 |
Why?
|
Molecular Docking Simulation | 1 | 2019 | 49 | 0.040 |
Why?
|
Enzyme Stability | 1 | 2019 | 39 | 0.040 |
Why?
|
Protein Unfolding | 1 | 2019 | 13 | 0.040 |
Why?
|
Gelatin | 1 | 2019 | 26 | 0.040 |
Why?
|
Protein Aggregates | 1 | 2019 | 24 | 0.040 |
Why?
|
Static Electricity | 1 | 2019 | 90 | 0.040 |
Why?
|
High-Throughput Screening Assays | 1 | 2019 | 58 | 0.040 |
Why?
|
Workflow | 1 | 2019 | 81 | 0.040 |
Why?
|
Drug Interactions | 1 | 2019 | 244 | 0.040 |
Why?
|
Cattle | 1 | 2019 | 378 | 0.040 |
Why?
|
Proteolysis | 1 | 2019 | 114 | 0.040 |
Why?
|
Protein Structure, Secondary | 1 | 2019 | 333 | 0.040 |
Why?
|
Delayed-Action Preparations | 1 | 2017 | 110 | 0.040 |
Why?
|
Macrophages | 1 | 2020 | 582 | 0.040 |
Why?
|
Protein Structure, Tertiary | 1 | 2019 | 740 | 0.030 |
Why?
|
para-Aminobenzoates | 1 | 2016 | 6 | 0.030 |
Why?
|
Models, Biological | 1 | 2023 | 1766 | 0.030 |
Why?
|
Freeze Drying | 1 | 2015 | 15 | 0.030 |
Why?
|
Biopharmaceutics | 1 | 2015 | 1 | 0.030 |
Why?
|
Benzamides | 1 | 2016 | 234 | 0.030 |
Why?
|
Camptothecin | 1 | 2015 | 195 | 0.030 |
Why?
|
Fourier Analysis | 1 | 2014 | 128 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2014 | 315 | 0.030 |
Why?
|
In Vitro Techniques | 1 | 2015 | 996 | 0.030 |
Why?
|
Multigene Family | 1 | 2014 | 202 | 0.030 |
Why?
|
Neutrons | 1 | 2012 | 57 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2014 | 295 | 0.030 |
Why?
|
Middle Aged | 1 | 2011 | 26173 | 0.020 |
Why?
|
Pilot Projects | 1 | 2014 | 872 | 0.020 |
Why?
|
Capsules | 1 | 2010 | 37 | 0.020 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2010 | 152 | 0.020 |
Why?
|
Software | 1 | 2014 | 669 | 0.020 |
Why?
|
Choline | 1 | 2009 | 24 | 0.020 |
Why?
|
Microscopy | 1 | 2009 | 87 | 0.020 |
Why?
|
Microscopy, Atomic Force | 1 | 2005 | 53 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2009 | 824 | 0.020 |
Why?
|